Dr. Nagaraju Sakkani is currently employed as a Process Chemist at Olon USA, where he focuses on the Process development of active pharmaceutical ingredients (APIs) and advanced intermediates. Before this role, he was a member of the Medicines for All Institute, where he contributed to the development of efficient and scalable processes for API's and advanced intermediates.
He earned his Ph.D. in 2018 and subsequently worked as a Research Scientist at Salala Organic Limited, where his research centered on drug discovery.
He further strengthened his expertise through two postdoctoral appointments. His first postdoctoral research was conducted at the Fujian Institute of Research on the Structure of Matter (FJIRSM), China, where he specialized in asymmetric organocatalysis. He later joined the University of Texas at San Antonio (UTSA), where his work focused on the development of innovative synthetic methodologies utilizing organocatalysis and photocatalysis.
Dr. Nagaraju Sakkani is currently employed as a Process Chemist at Olon USA, where he focuses on the Process development of active pharmaceutical ingredients (APIs) and advanced intermediates. Before this role, he was a member of the Medicines for All Institute, where he contributed to the development of efficient and scalable processes for API's and advanced intermediates.
He earned his Ph.D. in 2018 and subsequently worked as a Research Scientist at Salala Organic Limited, where his research centered on drug discovery.
He further strengthened his expertise through two postdoctoral appointments. His first postdoctoral research was conducted at the Fujian Institute of Research on the Structure of Matter (FJIRSM), China, where he specialized in asymmetric organocatalysis. He later joined the University of Texas at San Antonio (UTSA), where his work focused on the development of innovative synthetic methodologies utilizing organocatalysis and photocatalysis.